IP Library Granted Patent US 12685779
Granted Patent B2
US 12685779 · App. 19/108,248 · Granted Jul 21, 2026

Complex

Inventors: Naozumi Harada (Tokyo, JP); Tadashi Inoue (Tokyo, JP); Takatoshi Soga (Tokyo, JP); Ayaka Matsumoto (Tokyo, JP)
Assignee: UNITED IMMUNITY, CO., LTD.
A61K47/61
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12685779
App. No.
19/108,248
Granted
Jul 21, 2026
Kind
B2
Abstract

An object is to provide a technique that improves the poor solubility of a compound of formula (1) in water and further suppresses the cytokine excessive release action and bone marrow toxicity of the compound of formula (1). This object is achieved by a complex comprising a modified polysaccharide containing a hydrophobic group, and a compound represented by formula (1).

Claims (7)

1 . A solution comprising a complex comprising a modified polysaccharide containing a hydrophobic group, and Telratolimod, wherein the polysaccharide that forms the modified polysaccharide comprises pullulan, and the hydrophobic group comprises a hydrophobic group having a sterol skeleton.

2 . The solution according to claim 1 , wherein the modified polysaccharide has a weight average molecular weight of 5000 to 2,000,000.

3 . The solution according to claim 1 , wherein the complex is gel particles.

4 . The solution according to claim 3 , wherein Telratolimod is contained within the gel particles.

5 . The solution according to claim 1 , wherein the mass ratio of the modified polysaccharide to Telratolimod (mass of modified polysaccharide/mass of Telratolimod) is 2 to 20.

6 . The solution according to claim 1 , wherein the complex has a scattering intensity average particle size of 10 to 200 nm.

7 . The solution according to claim 1 , which is used in combination with an immune checkpoint inhibitor.